Clinical Trial Update: ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE [Phase 3]

View source ↗

Summary

Phase 3 trial update for ravulizumab (ARTEMIS) in CKD patients to protect against CSA-AKI and MAKE events; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Chronic Kidney Disease, CKD | Phase 3 | Status: COMPLETED